Quantcast

Latest MCRPC Stories

2014-06-02 08:30:44

Phase 2 study data presented at the 50th annual meeting of the American Society of Clinical Oncology HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA(®)) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use of abiraterone acetate plus prednisone (5 mg once daily) in patients with non-metastatic castration-resistant prostate cancer...

2014-05-14 16:29:31

- Research in hematological malignancies features: ibrutinib (IMBRUVICA®), siltuximab (SYLVANT(TM)) and daratumumab; research in solid tumors features: abiraterone acetate (ZYTIGA®), ARN-509, trabectedin and JNJ-42756493 RARITAN, N.J., May 14, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced data related to seven compounds have been selected for presentation at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May...

2014-05-14 16:29:25

Eight abstracts will highlight enzalutamide studies in prostate and breast cancers NORTHBROOK, Ill. and SAN FRANCISCO, May 14, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) announced that eight enzalutamide abstracts will be presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30-June 3 in Chicago. http://photos.prnewswire.com/prnvar/20140416/84970 The...

2014-04-02 04:21:20

WHIPPANY, N.J., April 2, 2014 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that the company has begun to enroll patients in a trial studying Xofigo(®) (radium Ra 223 dichloride) injection in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC). The randomized, double-blind, placebo-controlled...

2014-01-29 08:29:12

Studies address technical sensitivity, specificity, pharmacodynamics, heterogeneity and patient selection relevant to prostate cancer patient management SAN DIEGO and SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ -- Epic Sciences, in collaboration with the company's academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical College, University of Michigan, and Progenics Pharmaceuticals, will present six novel...

2012-12-20 05:03:29

Digital Science Press, Inc. announces UroToday.com is expanding editorial content with more indepth clinical education for the urologists and medical oncologists on immunotherapy treatments for men with metastatic castration-resistant prostate cancer (mCRPC). UroToday publishes two year-end review white papers: Best of Prostate and the Best of mCRPC featuring interviews with prostate cancer experts. Berkeley, CA (PRWEB) December 19, 2012 Now in its tenth year as an online urology-medical...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.